47,476 Shares in Becton, Dickinson and Company $BDX Acquired by Ravenstone Capital Management Inc.

Ravenstone Capital Management Inc. acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 47,476 shares of the medical instruments supplier’s stock, valued at approximately $7,465,000. Becton, Dickinson and Company comprises about 3.7% of Ravenstone Capital Management Inc.’s investment portfolio, making the stock its 17th largest holding.

Several other institutional investors have also modified their holdings of BDX. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC lifted its holdings in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the last quarter. United Bank boosted its position in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares in the last quarter. Marshall Wace LLP increased its stake in Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock valued at $5,491,000 after purchasing an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC increased its position in shares of Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 0.3%

Shares of BDX opened at $166.19 on Monday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $45.79 billion, a P/E ratio of 42.07, a PEG ratio of 11.80 and a beta of 0.19. The firm’s 50-day moving average is $151.85 and its two-hundred day moving average is $163.37.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,189 shares of company stock worth $765,661 in the last three months. 0.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on BDX. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. Bank of America cut their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Finally, Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $180.93.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.